<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003957</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067156</org_study_id>
    <secondary_id>FCCC-98052</secondary_id>
    <secondary_id>NCI-G99-1541</secondary_id>
    <nct_id>NCT00003957</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Trial of Multiple Cycles of Sequential High Dose Chemotherapy for Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell&#xD;
      transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus&#xD;
      peripheral stem cell transplantation in treating patients who have relapsed non-Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine how many patients with chemotherapy sensitive relapsed non-Hodgkin's&#xD;
      lymphoma receiving sequential high dose chemotherapy achieve a collection of a minimum 5&#xD;
      million CD34+ cells/kg in one large volume apheresis. II. Determine the feasibility and&#xD;
      safety of this regimen in these patients. III. Determine disease free and overall survival of&#xD;
      patients receiving this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive cyclophosphamide IV over 1 hour followed by paclitaxel IV over 24&#xD;
      hours on day 1. Filgrastim (G-CSF) and stem cell factor (SCF) are administered subcutaneously&#xD;
      beginning on day 3 for approximately 7-14 days (until the completion of leukapheresis).&#xD;
      Peripheral blood stem cells (PBSC) are collected over 3-5 days. Three weeks after&#xD;
      leukapheresis is completed, patients receive cytarabine IV over 2 hours twice a day on days&#xD;
      -6 to -3. Mitoxantrone IV is administered over 1 hour on day -6. CD34+ PBSC are reinfused on&#xD;
      day 0. Four weeks later, patients receive etoposide IV over 11 hours on day -2 and melphalan&#xD;
      IV over 30 minutes twice on day -1. CD34+ PBSC are reinfused on day 0. Concurrent G-CSF is&#xD;
      administered subcutaneously and continues until blood counts recover. Patients are followed&#xD;
      at 4 weeks, every 3 months for the first 2 years, and then every 6 months for the next 2&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Actual">August 2001</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">3</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant human stem cell factor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed follicular or diffuse large cell, diffuse&#xD;
        mixed, or immunoblastic non-Hodgkin's lymphoma (working formulation D, F, G, or H) First&#xD;
        relapse from a complete response or complete response unconfirmed after a front line&#xD;
        chemotherapy regimen (e.g., CHOP-like regimen) Second relapse from partial response after&#xD;
        2-4 courses of second line standard dose chemotherapy (e.g., MINE, EPOCH, or&#xD;
        platinum-containing regimens) No more than 1 salvage treatment regimen No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not&#xD;
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at&#xD;
        least 100,000/mm3 Hepatic: Transaminases no greater than 2 times upper limit of normal&#xD;
        Bilirubin no greater than 2 mg/dL (unless due to biopsy proven lymphoma) No chronic viral&#xD;
        hepatitis Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60&#xD;
        mL/min No overt renal insufficiency Cardiovascular: LVEF at least 45% No congestive heart&#xD;
        failure (New York Heart Association class III or IV) No myocardial infarction within past 6&#xD;
        months No uncontrolled hypertension (diastolic blood pressure greater than 115 mmHg) No&#xD;
        unstable angina No coronary angioplasty within past 6 months No uncontrolled atrial or&#xD;
        ventricular cardiac arrhythmias Pulmonary: DLCO and FEV1 at least 45% of predicted No&#xD;
        severe pulmonary disease No seasonal or recurrent asthma within past 10 years No asthmatic&#xD;
        symptoms (e.g., wheezing) related to current respiratory tract infection No concurrent&#xD;
        symptoms of bronchoconstriction No anaphylactic/anaphylactoid-type event manifested by&#xD;
        disseminated urticaria, laryngeal edema, and/or bronchospasm Other: Not pregnant or nursing&#xD;
        Negative pregnancy test Fertile patients must use effective contraception HIV negative No&#xD;
        prior malignancy within the past 5 years except carcinoma in situ of the cervix or basal&#xD;
        cell or squamous cell skin cancer No severe medical or psychiatric illness (including&#xD;
        severe depression) No active peptic ulcer disease No poorly controlled diabetes No allergy&#xD;
        to insect vemons No active history of angioedema or recurrent urticaria (an isolated&#xD;
        episode of urticaria is allowed) No active infection No fever greater than 38.2 degrees C&#xD;
        (except fevers due to B symptoms) No allergy to E. coli derived products&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 week since prior hematopoietic&#xD;
        growth factors Chemotherapy: See Disease Characteristics At least 4 weeks since prior&#xD;
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to&#xD;
        relapsed sites of vital organs (except as part of initial treatment) At least 4 weeks since&#xD;
        prior palliative radiotherapy to bulky nodes Surgery: At least 2 weeks since prior major&#xD;
        surgery Other: No other concurrent investigational drugs No concurrent beta adrenergic&#xD;
        blocking agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell J. Schilder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Russell Schilder, MD</name_title>
    <organization>FCCC</organization>
  </responsible_party>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

